Confidential Third Amendment to SK2014-1899Exclusive License Agreement • May 4th, 2020 • Aduro Biotech, Inc. • Pharmaceutical preparations
This Third Amendment to the Exclusive License Agreement (this “Third Amendment”) to that certain Exclusive License Agreement for Institutions’ Technology “Compositions & Methods for Altering Second Messenger Signaling,” effective as of December 18, 2014 (together with all amendments prior the date hereof, the “License Agreement”), by and between Memorial Sloan Kettering Cancer Center, a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065, The Rockefeller University, a New York not-for-profit corporation with principal offices at 1230 York Avenue, New York, NY 10065, Rutgers, The State University of New Jersey, having its statewide Office of Technology Commercialization at 3 Rutgers Plaza, New Brunswick, New Jersey 08901, and University of Bonn, all of which will be collectively referred to as “Institutions” and Aduro Biotech, Inc., a corporation with principal offices located at 740 Heinz Avenue, Berkeley, CA 94710 (“Licensee”), is entered
TERMINATION AGREEMENTTermination Agreement • May 4th, 2020 • Aduro Biotech, Inc. • Pharmaceutical preparations
